Log in to save to my catalogue

Raltegravir for the treatment of patients co-infected with HIV and tuberculosis (ANRS 12 180 Reflate...

Raltegravir for the treatment of patients co-infected with HIV and tuberculosis (ANRS 12 180 Reflate...

https://devfeature-collection.sl.nsw.gov.au/record/TN_cdi_proquest_miscellaneous_1534815137

Raltegravir for the treatment of patients co-infected with HIV and tuberculosis (ANRS 12 180 Reflate TB): a multicentre, phase 2, non-comparative, open-label, randomised trial

About this item

Full title

Raltegravir for the treatment of patients co-infected with HIV and tuberculosis (ANRS 12 180 Reflate TB): a multicentre, phase 2, non-comparative, open-label, randomised trial

Publisher

London: Elsevier Ltd

Journal title

The Lancet infectious diseases, 2014-06, Vol.14 (6), p.459-467

Language

English

Formats

Publication information

Publisher

London: Elsevier Ltd

More information

Scope and Contents

Contents

Summary Background Concurrent treatment of HIV and tuberculosis is complicated by drug interactions. We explored the safety and efficacy of raltegravir as an alternative to efavirenz for patients co-infected with HIV and tuberculosis. Methods We did a multicentre, phase 2, non-comparative, open-label, randomised trial at eight sites in Brazil and F...

Alternative Titles

Full title

Raltegravir for the treatment of patients co-infected with HIV and tuberculosis (ANRS 12 180 Reflate TB): a multicentre, phase 2, non-comparative, open-label, randomised trial

Identifiers

Primary Identifiers

Record Identifier

TN_cdi_proquest_miscellaneous_1534815137

Permalink

https://devfeature-collection.sl.nsw.gov.au/record/TN_cdi_proquest_miscellaneous_1534815137

Other Identifiers

ISSN

1473-3099

E-ISSN

1474-4457

DOI

10.1016/S1473-3099(14)70711-X

How to access this item